Verona Pharma PLC Holding(s) in Company (1066G)
August 03 2016 - 4:03AM
UK Regulatory
TIDMVRP
RNS Number : 1066G
Verona Pharma PLC
03 August 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
(i)
1. Identity of the issuer or
the underlying issuer of existing
shares to which voting rights VERONA PHARMA PLC
are attached: ii
----------------------------------------------------------- ------------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-------------------------------------------------------------------------------------------------------------
--
An acquisition or disposal of voting rights X
----------------------------------------------------------- ------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------- ------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------- ------------------------------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------- ------------------------------------------------
Other (please specify) :
------------------------------------------------
ARIX BIOSCIENCE HOLDINGS LTD
3. Full name of person(s) &
subject to the notification WALES LIFE SCIENCES INVESTMENT
obligation: iii FUND LP 'AFFILIATED' ENTITIES
----------------------------------------------------------- ------------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):iv
----------------------------------------------------------- ------------------------------------------------
5. Date of the transaction
and date on 28 JULY 2016
which the threshold is crossed
or reached: v
----------------------------------------------------------- ------------------------------------------------
6. Date on which issuer 29 JULY 2016
notified:
----------------------------------------------------------- ------------------------------------------------
7. Threshold(s) that is/are
crossed or reached: vi,
vii 10.6%
----------------------------------------------------------- ------------------------------------------------
8. Notified details:
-----------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares viii, ix
-----------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using the
ISIN CODE
-------------- ---------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights x
Shares Voting
Rights
-------------- ------------- ------------ ------------ ------------------------------ ----------------------
Direct Direct Indirect Direct Indirect
xi xr r
-------------- ------------- ------------ ------------ ------------ ---------------- ----------- ---------
10.6%
---------
ORDINARY 207 ,500,000 207,500,000 272,017,620 272,017,620
-------------- ------------- ------------ ------------ ------------ ---------------- ----------- ---------
B: Qualifying Financial Instruments
-------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting %of voting
instrument date XI Conversion rights that rights
II Period xrv may be acquired
if the instrument
is exercised!
converted.
------------------ ----------- ------------ ------------------- -----------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
XV, XV i
---------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting %of voting
instrument price date Conversion rights rights xix,
XV II period instrument refers XX
xviii to
------------------ --------- ----------- ------------ ------------------- --------------------
Nominal Delta
---------- --------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
272,017,620 10.6%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held, if
applicable: xxi
Wales Life Sciences Investment Fund LP previously held 20.55%,
it now holds 8.1% as stand alone entity.
Arix Bioscience Holdings Ltd previously held 0%, it now holds
2.5% as a stand-alone entity following the new share issue.
Combined holding 10.6%
Proxy Voting:
------------------------------------------
10. Name of the proxy holder:
--------------------------------------
11. Number of voting rights proxy
holder will cease to hold:
--------------------------------------
12. Date on which proxy holder will
cease to hold voting rights:
--------------------------------------
13. Additional information:
--------------------------------
14. Contact name:
--------------------------------
15. Contact telephone number:
--------------------------------
Note: Annex should only be submitted to the FCA not the
issuer
Annex: Notification of major interests in shares xx ll
A: Identity of the persons or legal entity subject
to the notification obligation
--------------------------------------------------------------------
Full name
(including legal form of Arix Bioscience Holdings Ltd
legal entities) Wales Life Sciences Investment
Fund LP
--------------------------------- ---------------------------------
Contact address
(registered office for legal 20 Berkeley Square London
entities) W1J 6EQ
--------------------------------- ---------------------------------
Phone number & email 020-7290-1050
--------------------------------- ---------------------------------
Other useful information
(at least legal representative
for legal persons)
--------------------------------- ---------------------------------
8: Identity of the notifier, if applicable
------------------------------------------------------------------
Full name
James Rawlingson
------------------------------------ ----------------------------
Contact address
20 Berkeley Square London
W1J 6EQ
------------------------------------ ----------------------------
Phone number & email
020-7290-1050
lnfo@arixbioscience .com
------------------------------------ ----------------------------
Other useful information
(e.g. functional relationship
with the person or legal
entity subject to the notification
obligation)
------------------------------------ ----------------------------
C: Additional information
For notes on how to complete form TR-1 please see the FCA
website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUAARUPQUMW
(END) Dow Jones Newswires
August 03, 2016 04:03 ET (08:03 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
